As with many drugs, Xanax stays in the body long after a person stops feeling its effects. Experts use a half-life measurement to determine how long a drug stays in the body. A drug’s half-life is the time it takes the body to eliminate half of it.

The half-life of Xanax is 8–16 hoursTrusted Source in a healthy person, with a mean half-life of 11 hours. This is shorter than that of many other benzodiazepines.

However, the term “half-life” can be misleading. This is because it takes four to five half-lives for the body to eliminate a drug. This means that it may take an average of 44–55 hours, or about 2 days, for Xanax to leave the body.

In one 2019 study, researchers reported that they could detect Xanax in a person’s saliva for up to 2.5 days after their last dose.CONTACT;text calls and whatsapp;+15136660803,wirkr;martinsscott1986

alprazolam pills

xanax pills 2mg

Blue Xanax, like all forms of Xanax, is prescribed for the short-term treatment of the symptoms of anxiety disorders or panic disorders.

Xanax works by reducing activity in the CNS (central nervous system) and brain. This mechanism of action induces a sense of calm, intensifying the effects of a naturally occurring brain chemical, GABA (gamma-aminobutyric acid).

First approved by the FDA in 1981, Xanax is still widely prescribed in spite of its habit-forming potential.text calls and whatsapp;+15136660803

xanax1mg

BUFFALO, NY- November 15, 2023 – A new #editorial paper was #published in Oncotarget's Volume 14 on March 31, 2023, entitled, “Obesity paradox and lung cancer, metformin-based therapeutic opportunity?”

In their recent editorial, researchers Pedro Barrios-Bernal, Norma Hernández-Pedro, Luis Lara-Mejía, and Oscar Arrieta from Instituto Nacional de Cancerología discuss obesity, diabetes and lung cancer. Obesity is a complex multifactorial disease with detrimental effects on health. This disease induces a proinflammatory state, innate and adaptative immune system dysfunction, and immune exhaustion, which in conjunction promote cancer growth. 

Although obesity and type 2 diabetes mellitus (T2DM) have been associated with lung cancer (LC) development, several confounding factors, such as chronic inflammation, high insulin levels, microbiome, as well as the oncogenic potential of growth and sexual hormones, have introduced uncertainty and avoid the fully recognition of this relationship [1, 2]. Thus, therapies that can bring potential therapeutic effects to both comorbidities are being tested globally and their effect on cancer cells.

“Altogether, there is a strong relationship between high BMI and increase survival in different LC stages and in combination with some anticancer therapies. Metformin has been shown to be a metabolism modifier that may adapt signaling pathways and immune sensitivity in tumor microenvironment.”

DOI - https://doi.org/10.18632/oncotarget.28432

Correspondence to - Oscar Arrieta -  ogarrieta@gmail.com

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28432

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, obesity, lung cancer, metformin, tyrosine-kinase inhibitors, BMI, EGFR, obesity paradox

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Oncotarget

The Obesity Paradox: Metformin for Diabetes and Lung Cancer?

Metformin is a commonly prescribed medication for the management of type 2 diabetes. As a first-line treatment, it plays a crucial role in improving insulin sensitivity, reducing glucose production in the liver, and enhancing the body's response to insulin. For individuals with diabetes, monitoring the signs metformin is working is essential for assessing the effectiveness of the medication. It's important to note that individual responses to Metformin may vary, and any concerns or questions about its effectiveness should be discussed with a healthcare professional. Read More:- https://bit.ly/46xzJiG

Signs that Metformin is Working: Understanding the Impact on Diabetes Management

https://topsupplementnewz.com/Order-MetforminCBDGummies

Metformin CBD Gummies - Shocking Side Effect and Benefits Must Know?
Metformin CBD Gummies Reviews Many battles with pressure and tension in the advanced period of clamoring ways of life. Vanquishing these issues in a negligible time is hard. Using different enhancements to your eating routine and utilizing huge portions of medications can adversely affect your body and the individual taking them. Hence, looking for exceptional ways of managing ailments without unfortunate results is fundamental. Metformin CBD Gummies can be an enhancement that lessens the possibility of fostering specific medical conditions.

https://sites.google.com/view/metformin-cbd-gummies/

https://sites.google.com/view/metformin-cbd-gummies-reviews/

Metformin CBD Gummies – Is It a Scam or Legit Deal?

Metformin CBD Gummies Official Website, Improve Health & Helps In Pain Relief?

With the rise of Ozempic over the last year, I have been getting questions about alternatives - one such question that keeps popping up is around Berberine. And not just for weight loss but also for its anti inflammatory properties. So it was time to "revisit" Berberine and take a look at how its works and what its benefits are. Check it out! References to research are below along with the link to the original podcast episode 214 on Berberine.

As always, please like, share and subscribe. And if you feel like my teachings deserve a review, I would very much appreciate that! Thank you! :)

Refs;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233907/
https://www.sciencedirect.com/science/article/abs/pii/S0944711312001870
https://pubmed.ncbi.nlm.nih.gov/35469308/
https://pubmed.ncbi.nlm.nih.gov/34994821/
https://pubmed.ncbi.nlm.nih.gov/30466986/
https://pubmed.ncbi.nlm.nih.gov/36089660/
EP214 "The benefits of Berberine."  https://on.soundcloud.com/JadVrQwXumdidnux5

#336 Berberine Revisited - blood sugars, fat loss, inflammation & more.

Wie kann verhindert werden, dass sich aus einem Prädiabetes ein Typ-2-Diabetes entwickelt? Wie kann eine Remission erreicht werden? Welche Rolle spielt dabei die Reduzierung des Körpergewichts? Inwieweit können moderne Medikamente dabei helfen und wie wirken diese?

Darüber sprechen wir in der aktuellen Folge von O-Ton Diabetologie mit Prof. Dr. Andreas Birkenfeld. Der Facharzt für Innere Medizin, Endokrinologe und Diabetologe ist Ärztlicher Direktor der Klinik für Diabetologie, Endokrinologie und Nephrologie des Universitätsklinikums Tübingen. Zudem leitet er das Institut für Diabetesforschung und metabolische Erkrankungen (IDM) von Helmholtz Munich am DZD-Standort Tübingen.

Zur Folgen-Übersicht: https://bit.ly/4g87JqZ

Weiterführende Informationen:
•	Website der Klinik Innere Medizin IV am Universitätsklinikum Tübingen: https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/kliniken/medizinische-klinik/innere-medizin-iv 
•	Website des IDM: https://www.helmholtz-munich.de/diabetes-center/idm 
•	Adipositas-Fortbildung der DDG: https://adipositas-fortbildung.de/

O-TON Diabetologie

Wie gelingt die Remission des Prädiabetes und die Prävention des T2Diabetes, Herr Prof. Birkenfeld?

BUFFALO, NY- January 16, 2025 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 22 on December 2, 2024, entitled “Less frequent skin ulcers among patients with Werner syndrome treated with pioglitazone: findings from the Japanese Werner Syndrome Registry.”

Scientists from Chiba University in Japan and other institutions have discovered that the drug pioglitazone, commonly used to treat diabetes, may help prevent painful skin ulcers in people with Werner syndrome. Werner syndrome is a rare genetic condition that causes people to age faster than normal, leading to early gray hair, cataracts, and other age-related health problems. One of the most serious complications is skin ulcers, which affect nearly 70% of people with the disorder and can lead to severe pain, infections, and even amputations.

The study, led by first author Kazuto Aono and corresponding author Masaya Koshizaka, looked at 51 patients with Werner syndrome from the Japanese Werner Syndrome Registry. Over half of the patients had skin ulcers, and those with ulcers were generally older and had higher blood pressure. The research team found that patients who took pioglitazone were much less likely to have ulcers, even after accounting for age.

The research suggests that pioglitazone's ability to reduce inflammation helps wounds heal faster and prevents ulcers from forming. However, since the drug can cause side effects, like weaker bones, scientists recommend further studies to explore safer options, such as creams or gels made from pioglitazone that can be applied directly to the skin.

“Nanostructured hybrid materials loaded with pioglitazone are also being developed for clinical use and may be useful as wound dressings for ulcer treatment.” 

Although the study shows promising results, the authors emphasize that more long-term studies are needed to confirm how effective the treatment is besides the exploration of other factors, like diet and exercise, that may also help reduce the ulcers.

In conclusion, this study presents pioglitazone as a potential option to prevent skin ulcers in Werner syndrome patients. While further studies are needed, these findings provide hope for better treatments.

DOI - https://doi.org/10.18632/aging.206161

Corresponding author - Masaya Koshizaka - overslope@chiba-u.jp

Sign up for free Altmetric alerts about this article - 
https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206161

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, Werner syndrome, skin ulcer, metformin, pioglitazon, progeroid syndrome

About Aging-US

The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.

The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)

Please visit our website at https://www.Aging-US.com​​ and connect with us:

Facebook - https://www.facebook.com/AgingUS/
X - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/@AgingJournal
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/
Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc

MEDIA@IMPACTJOURNALS.COM

Aging (Aging-US)

Fewer Skin Ulcers in Werner Syndrome Patients Treated with Pioglitazone

Neue Diabetestechnologien und Behandlungsformen, aktuelle Forschungsergebnisse und Leitlinienupdates, Reizthemen der Gesundheitspolitik und der Digitalisierung – all dies sind Themen des Podcasts O-Ton Diabetologie. Dazu reden wir mit spannenden Persönlichkeiten aus der Diabetologie.

O-Ton Diabetologie, das sind Günter Nuber, Leiter des Teams Diabetologie im Medienverbund der MedTriX Deutschland und Chefredakteur der diabetes zeitung, Michael Reischmann, Ressortleiter Politik und Wirtschaft am Standort Wiesbaden, sowie Jochen Schlabing, ebenfalls Redakteur der MedTriX Group.

Den Podcast O-Ton Diabetologie gibt es alle 14 Tage mittwochs. Abonnieren Sie uns und machen Sie auch gerne Themenvorschläge. Kontakt zur Redaktion unter: o-ton-diabetologie@medtrix.group

This podcast aims to teach you how to understand your body, take care of yourself and learn how to constantly stack conditions in your favor. Integrative Health practitioner, Nutritional Therapist, Biohacker, Certified Iridologist, Personal trainer and Pilates instructor. I specialize in orthomolecular nutrition, long term sustainable weight loss, female hormones, metabolic health, sleep quality, brain health and more. Commit to learning how your body really works and achieve sustainable results.

The information in these podcast episodes is for informational purposes only and should not be taken as medical advice. All guest opinions are their own and do not reflect my own.

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Cancer and aging are two sides of age-related tumorigenesis.

The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.

The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)

Read about the Aging (Aging-US) Scientific Integrity Process: https://aging-us.com/scientific-integrity

New tracks tagged #metformin